ArticleInternational journal of clinical and experimental pathology2018
Inhibiting CtBP2 expression blocks development of esophageal squamous cell carcinoma through decreasing angiogenesis.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to explain the effects and mechanism of CtBP2 in the development of esophageal squamous cell carcinoma. In this study, we first evaluated CtBP2 protein expression of ESCC tumor and adjacent normal tissues by immunohistochemistry (IHC) and Western blot (WB) assay. Meanwhile, the number of vessels of ESCC and adjacent normal tissues were measured by immunofluorescence. In cell experiments, the effects of CtBP2 were evaluated by wound healing assay, flow cytometry detection, and EPC tube formation. The mechanisms of CtBP2 were investigated by immunofluorescence, qRT-PCR, WB, and EdU incorporation assay. In conclusion, CtBP2 inhibits ESCC
Indexed as
Identifiers
31938424PMC6958089W3026473602What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.